A Phase I Trial of Pox PSA vaccines (PROSTVAC(®)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

PURPOSE: Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (desi...

Descripción completa

Detalles Bibliográficos
Autores principales: DiPaola, RS, Plante, M, Kaufman, H, Petrylak, DP, Israeli, R, Lattime, E, Manson, K, Schuetz, T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360095/
https://www.ncbi.nlm.nih.gov/pubmed/16390546
http://dx.doi.org/10.1186/1479-5876-4-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360095/
https://www.ncbi.nlm.nih.gov/pubmed/16390546
http://dx.doi.org/10.1186/1479-5876-4-1

Ejemplares similares